retatrutide heart rate increase A new weight-loss drug called is generating excitement after clinical trial participants lost an average of 30% of their body weight, results that rival or even exceed weight-loss surgery. Researchers also Substack Series 3 of 6:

Published comparator research reports approximately 22.5% body weight reduction for tirzepatide (dual receptor agonist) and approximately 15% for semaglutide (single receptor agonist) in their respective trials

10.1111/dom.14166 [DOI] [PubMed] [Google Scholar] 20.Wharton S, Davies M, Dicker D, Lingvay I, Mosenzon O, Rubino DM, Pedersen SD (2022) Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice

At the same time, GLP-1 suppresses the release of glucagon, a hormone responsible for raising blood sugar levels

Patient enrollment in clinical studies is also based mainly on baseline A1C, and treatment of a comparator is sometimes chosen unrelated to its pathophysiologic effect on hyperglycemia

Of note, all cases of clinically significant RGV were RGV that precluded adequate examination

"Each medication has pros and cons," Osborn said